These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35878189)

  • 61. Association of Laryngeal Botulinum Neurotoxin Injection With Work Productivity for Patients With Spasmodic Dysphonia.
    Meyer TK; Spiekerman C; Kaye R; Blitzer A; Kamizi RS; Jiang L; Weaver EM
    JAMA Otolaryngol Head Neck Surg; 2021 Sep; 147(9):804-810. PubMed ID: 34351425
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bilateral Posterior Cricoarytenoid Myoneurectomy for Abductor Spasmodic Dysphonia.
    Benito DA; Ferster APO; Sataloff RT
    J Voice; 2020 Jan; 34(1):127-129. PubMed ID: 30174222
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
    Blitzer A; Brin MF; Stewart CF
    Laryngoscope; 1998 Oct; 108(10):1435-41. PubMed ID: 9778279
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
    Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia in a large cohort.
    Dharia I; Bielamowicz S
    Laryngoscope; 2020 Nov; 130(11):2659-2662. PubMed ID: 31837152
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
    Morzaria S; Damrose EJ
    J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Mayo Clinic Arizona Spasmodic Dysphonia Experience: A Demographic Analysis of 718 Patients.
    Patel AB; Bansberg SF; Adler CH; Lott DG; Crujido L
    Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):859-63. PubMed ID: 26024910
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Spasmodic dysphonia: An overview of clinical features and treatment options.
    Sanuki T
    Auris Nasus Larynx; 2023 Feb; 50(1):17-22. PubMed ID: 35697560
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Factors influencing long-term treatment response to botulinum toxin injection for spasmodic dysphonia.
    Kang MS; Lee SJ; Choi HS; Lim JY
    Clin Otolaryngol; 2021 Mar; 46(2):436-444. PubMed ID: 33260261
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Transoral radiofrequency of the terminal branches of the recurrent nerve in the treatment of adductor spasmodic dysphonia: our experience over 11 patients.
    Beyaert S; Delahaut G; Ambroise J; Lawson G; Bachy V; Hassid S; Delacroix L; Remacle M; Van der Vorst S
    Eur Arch Otorhinolaryngol; 2022 Sep; 279(9):4465-4472. PubMed ID: 35590079
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Vocal Parameters and Self-Perception in Individuals With Adductor Spasmodic Dysphonia.
    Rojas GVE; Ricz H; Tumas V; Rodrigues GR; Toscano P; Aguiar-Ricz L
    J Voice; 2017 May; 31(3):391.e7-391.e18. PubMed ID: 27866691
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes: comparing different botulinum toxin preparations.
    Truong DD; Bhidayasiri R
    Eur J Neurol; 2006 Feb; 13 Suppl 1():36-41. PubMed ID: 16417596
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Long-term Evaluation of Type 2 Thyroplasty with Titanium Bridges for Adductor Spasmodic Dysphonia.
    Sanuki T; Yumoto E
    Otolaryngol Head Neck Surg; 2017 Jul; 157(1):80-84. PubMed ID: 28463639
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Spasmodic dysphonia: a seven-year audit of dose titration and demographics in the Indian population.
    Nerurkar NK; Banu TP
    J Laryngol Otol; 2014 Jul; 128(7):649-53. PubMed ID: 24999662
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: clinician and patient perception.
    Braden MN; Johns MM; Klein AM; Delgaudio JM; Gilman M; Hapner ER
    J Voice; 2010 Mar; 24(2):242-9. PubMed ID: 19481417
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prospective study of patients' subjective responses to botulinum toxin injection for spasmodic dysphonia.
    Liu TC; Irish JC; Adams SG; Durkin LC; Hunt EJ
    J Otolaryngol; 1996 Apr; 25(2):66-74. PubMed ID: 8683655
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia.
    Holzer SE; Ludlow CL
    Laryngoscope; 1996 Jan; 106(1 Pt 1):86-92. PubMed ID: 8544635
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Botulinum toxin injections for the treatment of spasmodic dysphonia.
    Watts CC; Whurr R; Nye C
    Cochrane Database Syst Rev; 2004; 2004(3):CD004327. PubMed ID: 15266530
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Consensus-Based Attributes for Identifying Patients With Spasmodic Dysphonia and Other Voice Disorders.
    Ludlow CL; Domangue R; Sharma D; Jinnah HA; Perlmutter JS; Berke G; Sapienza C; Smith ME; Blumin JH; Kalata CE; Blindauer K; Johns M; Hapner E; Harmon A; Paniello R; Adler CH; Crujido L; Lott DG; Bansberg SF; Barone N; Drulia T; Stebbins G
    JAMA Otolaryngol Head Neck Surg; 2018 Aug; 144(8):657-665. PubMed ID: 29931028
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Vocal aging and adductor spasmodic dysphonia: response to botulinum toxin injection.
    Cannito MP; Kahane JC; Chorna L
    Clin Interv Aging; 2008; 3(1):131-51. PubMed ID: 18488884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.